(Q36658188)

15 August 2017

1 reference

title

The use of vascular biomarkers and imaging studies in the early clinical development of anti-tumour agents targeting angiogenesis (English)

1 reference

15 August 2017

0 references

Drevs J

1

1 reference

15 August 2017

Schneider V

series ordinal

2

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 December 2006

1 reference

Journal of Internal Medicine

15 August 2017

published in

1 reference

15 August 2017

volume

260

1 reference

15 August 2017

issue

6

1 reference

15 August 2017

page(s)

517-529

1 reference

Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01727.X

Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01727.X

Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01727.X

Vascular growth factors and lymphangiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01727.X

Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01727.X

A physiologic imaging pilot study of breast cancer treated with AZD2171.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01727.X

Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01727.X

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01727.X

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01727.X

Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01727.X

Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01727.X

Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01727.X

Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer a

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01727.X

In vivo evaluation of 111In-DTPA-N-TIMP-2 in Kaposi sarcoma associated with HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01727.X

10.1111/J.1365-2796.2006.01727.X

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference